

Targeting Tumors with High Mutational Burden: Treating Patients with Advanced Non-Melanoma Skin Cancers

Toolkit

Non-Melanoma Skin Cancer: Identification and Management

Resource	Address
Ascierto PA, Schadendorf D, et al. Immunotherapy in non-melanoma skin cancer: Updates and new perspectives. <i>Drugs Context</i> . 2019;8:212583.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434981/
Chang ALS, Tran DC, Cannon JGD, et al. Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. <i>J Am Acad Dermatol</i> . 2019;80:564-566.	https://www.jaad.org/article/S0190-9622(18)32471-X/fulltext
Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. <i>Immunity</i> . 2013;39:1-10.	https://pubmed.ncbi.nlm.nih.gov/23890059/
Chong C, Goh M, Proceddu S, Rischin D, Lim AM. The current treatment landscape of cutaneous squamous cell carcinoma. <i>Am J Clin Dermatol</i> . 2023;24:25-40.	https://pubmed.ncbi.nlm.nih.gov/36512176/
Cives M, Mannavola F, Lospalluti L, et al. Non-melanoma skin cancers: Biological and clinical features. <i>Int J Mol Sci</i> . 2020;21:5394.	https://pubmed.ncbi.nlm.nih.gov/32751327/
Danesh MJ, Menge TD, Helliwell L, Mahalingam M, Waldman A. Adherence to the National Comprehensive Cancer Network criteria of complete circumferential peripheral and deep margin assessment in treatment of high-risk basal and squamous cell carcinoma. <i>Dermatol Surg</i> . 2020;46:1473-1480.	https://pubmed.ncbi.nlm.nih.gov/32149872/
Dummer R, Guminksi A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. <i>Br J Dermatol</i> . 2020;182:1369-1378.	https://pubmed.ncbi.nlm.nih.gov/31545507/
García-Foncillas J, Tejera-Vaquerizo A, Sanmartin O, et al. Update on management recommendations for advanced cutaneous squamous cell carcinoma. <i>Cancers (Basel)</i> . 2022;14:629.	https://pubmed.ncbi.nlm.nih.gov/35158897/
Geidel G, Heidrich I, Kott J, Schneider SW, Pantel K, Gebhardt C. Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma. <i>NPJ Precis Oncol</i> . 2022;6:17.	https://pubmed.ncbi.nlm.nih.gov/35322182/
Hernandez L, Mohsin N, Levin N, Dreyfuss I, Frech F, Nouri K. Basal cell carcinoma: An updated review of pathogenesis and treatment options. <i>Dermatol Ther</i> . 2022;35:e15501.	https://pubmed.ncbi.nlm.nih.gov/35393669/

Hoorens I, Batteauw A, Van Maele G, Lapiere K, Boone B, Ongenaë K. Mohs micrographic surgery for basal cell carcinoma: Evaluation of the indication criteria and predictive factors for extensive subclinical spread. <i>Br J Dermatol.</i> 2016;174:847-852.	https://pubmed.ncbi.nlm.nih.gov/26595159/
Hu W, Fang L, Ni R, Zhang H, Pan G. Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years. <i>BMC Cancer.</i> 2022;22:836.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339183/
Johnson TM, Smith NR. Mohs surgery versus standard local excision for basal cell carcinoma, squamous cell carcinoma, and melanoma skin cancer. <i>Facial Plast Surg.</i> 2020;36:133-140.	https://pubmed.ncbi.nlm.nih.gov/32413920/
Krakowski AC, Hafeez F, Westheim A, Pan EY, Wilson M. Advanced basal cell carcinoma: What dermatologists need to know about diagnosis. <i>J Am Acad Dermatol.</i> 2022;86(6 suppl):S1-S13.	https://pubmed.ncbi.nlm.nih.gov/35577405/
Migden M, Farberg AS, Dummer R, Squittieri N, Hanke CW. A review of hedgehog inhibitors sonidegib and vismodegib for treatment of advanced basal cell carcinoma. <i>J Drugs Dermatol.</i> 2021;20:156-165.	https://pubmed.ncbi.nlm.nih.gov/33538567/
Morgan FC, Ruiz ES, Karia PS, Besaw RJ, Neel VA, Schmults CD. Brigham and Women's Hospital tumor classification system for basal cell carcinoma identifies patients with risk of metastasis and death. <i>J Am Acad Dermatol.</i> 2021;85:582-587.	https://pubmed.ncbi.nlm.nih.gov/33497751/
Morgan FC, Ruiz ES, Karia PS, Besaw RJ, Neel VA, Schmults CD. Factors predictive of recurrence, metastasis, and death from primary basal cell carcinoma 2 cm or larger in diameter. <i>J Am Acad Dermatol.</i> 2020;83:832-838.	https://pubmed.ncbi.nlm.nih.gov/31600531/
Naik P, Desai MB. Basal cell carcinoma: A narrative review on contemporary diagnosis and management. <i>Oncol Ther.</i> 2022;10:317-335.	https://pubmed.ncbi.nlm.nih.gov/35729457/
Paulson KG, Lahman MC, Chapuis AG, Brownell I. Immunotherapy for skin cancer. <i>Int Immunol.</i> 2019;31:465-475.	https://pubmed.ncbi.nlm.nih.gov/30753483/
Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study. <i>BMC Cancer.</i> 2017;17:332.	https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3286-5
Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. <i>N Eng J Med.</i> 2012;366:2171-2179.	https://www.nejm.org/doi/full/10.1056/nejmoa1113713
Shalhout S, Kaufman H, Emerick K, Miller DM. Immunotherapy for nonmelanoma skin cancer: Facts and hopes. <i>Clin Cancer Res.</i> 2022;28:2211-2220.	https://pubmed.ncbi.nlm.nih.gov/35121622/

Spiliopoulou P, Vornicova O, Genta S, Spreafico A. Shaping the future of immunotherapy targets and biomarkers in melanoma and non-melanoma cutaneous cancers. <i>Int J Mol Sci.</i> 2023;24:1294.	http://pubmed.ncbi.nlm.nih.gov/36674809/
Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. <i>Eur J Cancer.</i> 2020;128:83-102.	https://pubmed.ncbi.nlm.nih.gov/32113942/
Stratigos AJ, Sekulic A, Peris K, et al. LBA47 Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs). <i>Ann Oncol.</i> 2020;31(suppl 4):S1175-S1176.	https://www.annalsofoncology.org/article/S0923-7534(20)42359-2/abstract
Svoboda SA, Johnson NM, Phillips MA. Systemic targeted treatments for basal cell carcinoma. <i>Cutis.</i> 2022;109:E25-E31.	https://pubmed.ncbi.nlm.nih.gov/35960978/

Resources and Societies

Resource	Address
American Academy of Dermatology (AAD). Skin Cancer.	https://www.aad.org/media/stats-skin-cancer
American Cancer Society (ACS). Basal and Squamous Cell Skin Cancer.	https://www.cancer.org/cancer/basal-and-squamous-cell-skin-cancer.html
American College of Mohs Surgery (ACMS).	https://www.mohscollege.org/
American Society of Clinical Oncology (ASCO).	https://www.asco.org/
Centers for Disease Control and Prevention (CDC). What Is Skin Cancer? Last reviewed April 18, 2023.	https://www.cdc.gov/cancer/skin/basic_info/what-is-skin-cancer.htm
National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology. Basal Cell Skin Cancer. Version 1.2023.	https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1416
National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in oncology. Squamous Cell Skin Cancer. Version 1.2023.	https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1465
Skin Cancer Foundation. Basal Cell Carcinoma Overview. Last updated January 2022.	https://www.skincancer.org/skin-cancer-information/basal-cell-carcinoma/
Skin Cancer Foundation. Squamous Cell Carcinoma Overview. Last updated March 2023.	https://www.skincancer.org/skin-cancer-information/squamous-cell-carcinoma/

All URLs accessed May 19, 2023